Side-by-side · Research reference
BronchogenvsTestagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED16/35 cited
BAnimal-MechanisticHUMAN-REVIEWED11/41 cited
Bronchogen
Tetrapeptide Bioregulator · Khavinson-School
Research models: tissue culture / parenteral
Testagen
Bioregulator Peptide · Khavinson School
SQ · Abdomen · Cyclical
01Mechanism of Action
Parameter
Bronchogen
Testagen
Primary target
Bronchial epithelial cellsKuzubova 2015
Testicular tissue; proposed nuclear DNA interaction
Pathway
Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Downstream effect
Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015Titova 2017
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Feedback intact?
—
Unknown — no HPG axis data
Origin
Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
Antibody development
—
—
02Dosage Protocols
Parameter
Bronchogen
Testagen
Effective concentration (culture)
0.05 ng/mLZakutskiĭ 2006
Demonstrated in organotypic tissue culture of bronchial explants.
—
Treatment duration (animal)
1 month (30 days)Kuzubova 2015Titova 2017
Course duration in rat COPD models.
—
Evidence basis
Animal models (rat) / organotypic cultureTitova 2017Kuzubova 2015Zakutskiĭ 2006
No human clinical trials reported in available literature.
Animal mechanistic / in vitro onlyFedoreyeva 2011
Tissue specificity
Selective for bronchopulmonary tissue
Part of Khavinson organ-specific bioregulator series.
—
Typical protocol (anecdotal)
—
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
Frequency
—
Once daily or alternate days
Cycle length
—
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
Route
—
Subcutaneous
Reconstitution
—
Sterile water or bacteriostatic saline
Half-life
—
Unknown — likely minutes (short peptide)
04Side Effects & Safety
Parameter
Bronchogen
Testagen
Animal safety profile
No adverse effects reported in published rat studies
Limited safety data; only animal models available.
—
Human data
Absent — no clinical trials in humans reported
—
Long-term effects
Unknown — maximum study duration 30 days in animals
—
Injection site reactions
—
Erythema, mild irritation (potential)
Systemic effects
—
Unknown — no human safety data
Hormonal impact
—
No published data on testosterone, LH, FSH effects
Long-term safety
—
Unknown — no long-term studies
Absolute Contraindications
Bronchogen
—Testagen
- ·Active testicular malignancy
Relative Contraindications
Bronchogen
—Testagen
- ·Hormone-sensitive cancers (no data; theoretical caution)
- ·Pregnant or breastfeeding (no data)
05Administration Protocol
Parameter
Bronchogen
Testagen
1. Research context only
Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
2. Animal model protocol
In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017Kuzubova 2015
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
3. Organotypic culture
Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
4. Khavinson bioregulator tradition
Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
5. Cycle protocol
—
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.